48
The complexity of turning a new drug into a successful asset remains a hurdle even beyond the coveted FDA approval.
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
Included in this trendline
- In pharma’s competitive climate, companies need evidence beyond clinical trials
- The ability to pivot will be ‘key’ as pharma’s tariff threat looms
- Big Pharma’s new DTC play: partnering with digital health providers
Offered Free by: PharmaVoice and EVERSANA
See All Resources from: PharmaVoice and EVERSANA